EFFECTIVE DOSAGE OF RECOMBINANT SERPIN-FC FUSION PROTEIN FOR USE IN A METHOD OF TREATING AAT DEFICIENCY IN A SUBJECT
The present application relates to an effective dosage of an aqueous solution comprising an engineered AAT-Fc fusion dimeric protein for use in a method of treating or alleviating a symptom associated with aberrant serine protease activity in a subject in need thereof.
1 . A method of treating or alleviating a symptom associated with aberrant serine protease activity in a subject in need thereof, the method comprising: administering to the subject an AAT-Fc fusion protein by infusion at a first dose of about 10 to 120 mg/Kg on the first day of treatment and a subsequent dose of 10 to 120 mg/Kg every three or four weeks thereafter,
wherein the AAT-Fc fusion protein (i) comprises the amino acid sequence of SEQ ID NO: 1 or (ii) comprises an AAT polypeptide of SEQ ID NO: 2 and an Fc polypeptide of SEQ NO: 3.
2 . The method of claim 1 , comprising administering a first or subsequent dose of about 60 to 120 mg/Kg.
3 . The method of claim 1 , comprising administering a first or subsequent dose of about 40 to 80 mg/Kg.
4 . The method of claim 1 , 2 , or 3 , comprising administering a first or subsequent dose of about 80 mg/Kg.
5 . The method of claim 1 or 2 , comprising administering a first or subsequent dose of about 120 mg/Kg.
6 . The method of any one of claims 1-5 , wherein the subsequent dose is higher than the first dose or a previous subsequent dose.
7 . The method of any one of claims 1-5 , wherein the subsequent dose is lower than the first dose or a previous subsequent dose.
8 . The method of any one of claims 1-5 , wherein the subsequent dose is same as the first dose or a previous subsequent dose.
9 . The method of any one of claims 1 , 2 , or 5-8 , wherein the method comprises administering a first dose of about 120 mg/Kg on the first day of treatment and a subsequent dose every three weeks thereafter.
10 . The method of any one of claims 1 , 2 , or 5-8 , wherein the method comprises administering a first dose of about 120 mg/Kg on the first day of treatment and a subsequent dose every four weeks thereafter.
11 . The method of any one of claims 1-3 further comprising:
(a) determining the level of serine protease expression or activity in the subject prior to administration of a first dose to obtain a baseline of expression or activity;
(b) determining the level of serine protease expression or activity at a period of time at least three weeks after administering the first dose, or subsequent dose; and
(c) administering a subsequent dose of the AAT-Fc fusion protein that is equal to, or higher than, the previous dose of the AAT-Fc fusion protein when the serine protease expression or activity in the subject is equal to, or higher than, the baseline level obtained in step (a); or
(d) administering a subsequent dose of the AAT-Fc fusion protein that is lower than the previous dose when the serine protease expression or activity in the subject is lower than the baseline level obtained in step (a).
12 . The method of any one of claims 1-3 , further comprising:
(a) determining the level of AAT expression or activity in the subject prior to administration of a first dose to obtain a baseline of expression or activity;
(b) determining the level of AAT expression or activity at a period of time at least three weeks after administering the first dose, or subsequent dose; and
(c) administering a subsequent dose of the AAT-Fc fusion protein that is equal to or higher than the previous dose of the AAT-Fc fusion protein when the AAT expression or activity in the subject is equal to or lower than the baseline level obtained in step (a); or
(d) administering a subsequent dose of the AAT-Fc fusion protein that is lower than the previous dose when the AAT expression or activity in the subject is higher than the baseline level obtained in step (a).
13 . The method of any one of claims 1-3 , further comprising:
(a) determining the serum AAT level in the subject at a period of time at least three weeks after administering the first or subsequent dose of the AAT-Fc fusion protein to obtain a serum AAT level; and
(b) administering a subsequent dose of the AAT-Fc fusion protein that is equal to or higher than the previous dose of the AAT-Fc fusion protein when the serum AAT level in the subject is below the normal range; or
(c) administering a subsequent dose of the AAT-Fc fusion protein that is lower than the previous dose when the serum AAT level in the subject is higher than the normal range.
14 . The method of claim 13 , wherein the functional AAT levels are determined.
15 . The method of claim 13 or 14 , wherein the serum AAT level in the subject is below about 15 µM or above about 50 µM.
16 . The method of any one of claims 1-15 , wherein the AAT-Fc fusion protein is in an aqueous solution comprising:
about 5 mg/ml to about 100 mg/ml of the AAT-Fc fusion protein comprising the amino acid sequence of SEQ ID NO: 1;
about 5 mM Tris;
about 150 mM Trehalose;
about 100 mM Sucrose;
about 100 mM Proline;
about 2 mM Methionine; and
about 0.1% (w/v) Poloxamer;
wherein the pH of the aqueous solution is adjusted to about 7.3 using either hydrochloric acid or sodium hydroxide;
wherein the total ionic strength of the aqueous solution, excluding the contribution of the AAT-Fc fusion protein, is about 4.3 mM.
17 . The method of any one of claims 1-15 , wherein the AAT-Fc fusion protein is in an aqueous solution comprising:
about 5 mg/ml to about 100 mg/ml of the AAT-Fc fusion protein comprising the amino acid sequence of SEQ ID NO:1;
about 50 mM sodium phosphate;
about 125 mM sodium chloride;
about 2% (w/v) Trehalose dihydrate;
and about 0.01% (w/v) polysorbate 20.
18 . The method of 17, wherein the aqueous solution has a pH of about 7.0.
19 . The method of any one of claims 16-18 , wherein the aqueous solution comprises about 50 mg/ml of the AAT-Fc fusion protein.
20 . The method of any one of claims 1-19 , wherein the subject in need thereof has aberrant serine protease activity associated with a disease or disorder selected from the following: AAT deficiency, emphysema, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), allergic asthma, cystic fibrosis, cancers of the lung, ischemia-reperfusion injury, ischemia/reperfusion injury following cardiac transplantation, myocardial infarction, rheumatoid arthritis, septic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, type I and/or type II diabetes, pneumonia, sepsis, graft versus host disease (GVHD), a wound healing disease or disorder, Systemic lupus erythematosus, and Multiple sclerosis.
21 . The method of claim 20 , wherein the subject has an AAT deficiency.
22 . The method of claim 20 , wherein the subject has an infection that is selected from a bacterial infection, a fungal infection, or a viral infection.
23 . The method of any one of claims 1-22 , wherein the subject is a human.
24 . The method of any one of claims 1-23 , wherein the infusion is delivered over a period of about 30-120 minutes.
25 . The method of claim 24 , wherein the infusion is delivered over a period of about 30-60 minutes.
26 . The method of any one of claims 1-25 wherein the subject in need thereof has a serum AAT level of less than 20 µM prior to the first dose.
27 . The method of any one of claims 1-26 wherein the subject in need thereof has a serum AAT level of less than or equal to 11 µM prior to the first dose.
28 . A unit dose vial comprising:
about 5 mg/ml to about 100 mg/ml of the AAT-Fc fusion protein comprising the amino acid sequence of SEQ ID NO:1;
about 50 mM sodium phosphate;
about 125 mM sodium chloride;
about 2% (w/v) Trehalose dihydrate; and
about 0.01% (w/v) polysorbate 20.
29 . The unit dose vial of claim 28 , comprising about 50 mg/ml of the AAT-Fc fusion protein.
30 . The unit dose vial of any one of claim 28 or 29 , wherein the pH is about 7.0.